Tyra Biosciences (NASDAQ:TYRA) Sets New 52-Week Low – Time to Sell?

Tyra Biosciences, Inc. (NASDAQ:TYRA) reached a new 52-week low on Thursday . The company traded as low as $13.12 and last traded at $13.14, with a volume of 59641 shares. The stock had previously closed at $13.67.

Wall Street Analysts Forecast Growth

Several analysts have commented on the company. Wedbush reissued an “outperform” rating and issued a $28.00 price objective on shares of Tyra Biosciences in a report on Friday, October 25th. UBS Group initiated coverage on shares of Tyra Biosciences in a research note on Tuesday, January 7th. They issued a “buy” rating and a $28.00 price target on the stock. HC Wainwright restated a “buy” rating and set a $30.00 price objective on shares of Tyra Biosciences in a research report on Monday, January 13th. Finally, Bank of America raised shares of Tyra Biosciences from a “neutral” rating to a “buy” rating and increased their price objective for the company from $22.00 to $31.00 in a report on Friday, October 18th. Six research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $30.50.

Tyra Biosciences Trading Down 3.8 %

The stock’s fifty day moving average price is $15.11 and its 200-day moving average price is $18.81.

Tyra Biosciences (NASDAQ:TYRA) last released its quarterly earnings data on Thursday, November 7th. The company reported ($0.41) EPS for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.01). As a group, equities research analysts forecast that Tyra Biosciences, Inc. will post -1.57 EPS for the current fiscal year.

Insider Activity

In other news, Director Nina S. Kjellson sold 3,993 shares of the stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $16.36, for a total transaction of $65,325.48. Following the completion of the transaction, the director now directly owns 3,707,420 shares in the company, valued at approximately $60,653,391.20. This represents a 0.11 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders sold 21,998 shares of company stock worth $344,818 over the last ninety days. Corporate insiders own 15.40% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Alta Partners Management Company L.P. acquired a new position in shares of Tyra Biosciences in the 4th quarter worth approximately $56,716,000. Janus Henderson Group PLC purchased a new stake in Tyra Biosciences in the third quarter valued at approximately $24,994,000. Walleye Capital LLC lifted its stake in Tyra Biosciences by 306.5% during the third quarter. Walleye Capital LLC now owns 126,597 shares of the company’s stock worth $2,976,000 after purchasing an additional 95,451 shares in the last quarter. Polar Asset Management Partners Inc. purchased a new position in shares of Tyra Biosciences during the third quarter worth $2,071,000. Finally, Raymond James Financial Inc. acquired a new stake in shares of Tyra Biosciences in the fourth quarter valued at $761,000. Institutional investors and hedge funds own 84.14% of the company’s stock.

Tyra Biosciences Company Profile

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.